Hepatitis B virus reactivation and antiviral prophylaxis during lung cancer chemotherapy: A systematic review and meta-analysis

Yu-tuan Wu*, Xin Li*, Zi-li Liu*, Zhou Xu*, Wei Dai*, Ke Zhang, Jiu-song Wu, Bilal Arshad, Kai-nan Wu, Ling-quan Kong*

Department of Endocrine and Breast Surgery, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China

* These authors contributed equally to this work.
* huihuikp@163.com

Abstract

Background
Antiviral drugs have been recommended as prophylaxis for the reactivation of hepatitis B virus (HBV) infection in cancer patients undergoing chemotherapy. However, screening and antiviral prophylaxis for lung cancer remain controversial because of insufficient evidence.

Purpose
In this study, we investigate the absolute risk for HBV reactivation and the prophylactic effects of antiviral drugs in hepatitis B surface antigen (HBsAg)-positive lung cancer patients during chemotherapy.

Methods
We searched Pubmed, Embase, Cochrane, Web of Science and SinoMed from inception until 28 November 2016, and identified all potential relevant references with or without prophylactic use of antiviral therapy in HBsAg-positive lung cancer patients during chemotherapy. The primary outcome was the incidence of HBV reactivation, the secondary outcomes were the incidence of hepatitis, chemotherapy disruption and mortality.

Results
Eleven studies involving 794 patients were analyzed. The incidences of HBV reactivation in control group and antiviral prophylaxis group ranged from 0% to 38% (median, 21%, 95% CI: 0.17–0.25) and 0% to 7% (median, 4%, 95% CI: 0.02–0.06), respectively. Antiviral prophylaxis had significantly reduced the risk for HBV reactivation (RR, 0.22 [95% CI: 0.13–0.37], \( p < 0.0001 \)), hepatitis (RR, 0.35 [95% CI: 0.22–0.56], \( p < 0.0001 \)) and chemotherapy disruption (RR: 0.29 [95% CI, 0.15–0.55], \( p < 0.0002 \)) compared to those without antiviral
prophylaxis. There was no significant heterogeneity in the comparisons, and a fixed-model was used.

**Conclusion**

The risks of HBV reactivation and relevant complications are high in HBsAg-positive lung cancer patients receiving chemotherapy, and available evidences support HBV screening for antiviral prophylaxis before initiation of chemotherapy for lung cancer patients.

**Introduction**

Hepatitis B virus (HBV) infection is an important public and medical problem. A global systematic review reported that 248 million people were chronically infected with HBV worldwide[1]. This is particularly true in developing areas, especially in Asia, where the infection rates of HBV were of high prevalence[2, 3]. For those with chronic or resolved HBV infection, they are at risk for HBV reactivation (HBVR) when receiving immunosuppressive therapy for various diseases.

As more chemotherapy applications are carried out in cancer patients, HBVR during chemotherapy has become a common problem that cannot be ignored. The increased risk for HBVR had been reported commonly in hematological malignancies[4], additionally, corresponding data in solid tumors were also reported[5]. HBVR had been reported in 20%-50% of patients with chronic HBV infection undergoing cancer chemotherapy or immunosuppressive therapy[6]. The clinical complications of HBVR, varying from asymptomatic hepatitis to lifethreatening events[7–9], may cause interruption or early termination of systemic chemotherapy, even HBV-related death, which would cause poor prognosis undoubtedly[10]. Therefore, HBV screening is recommended for cancer patients undergoing chemotherapy, and antiviral prophylaxis is recommended for HBsAg-positive patients[6]. However, despite the risk for reactivation, guidelines in oncology do not recommend universal screening of HBV for patients undergoing chemotherapy for solid tumors because of insufficient evidence[11].

Recent meta-analyses had reported the increased risk for HBVR and effective antiviral prophylaxis during chemotherapy for hematologic tumors and solid tumors (mainly including breast cancer)[4, 12–14], but none had examined HBVR and antiviral prophylaxis during chemotherapy for lung cancer. Lung cancer is the second most frequent cancer diagnosed, and the most common causes of cancer death in both male and female[15, 16]. It has been reported that HBsAg-positive lung cancer patients may experience a high risk for HBVR during cytotoxic chemotherapy[7–10, 17–23].

Therefore, the purpose of this study was designed to investigate the risk for HBVR with or without antiviral prophylaxis and the prophylactic effects of antiviral drugs in reducing the risk for HBVR and the relevant complications in HBsAg-seropositive lung cancer patients receiving chemotherapy.

**Materials and methods**

All the procedures of the systematic review and meta-analysis were conducted according to the MOOSE guidelines(Meta-analysis of Observational Studies in Epidemiology)[24]. We followed an established protocol which had been registered in PROSPERO (International prospective register of systematic reviews)[25], and the record is available on https://www.crd.york.ac.uk/PROSPERO/ (Registration number: CRD42016053110).
Search strategy
We searched Pubmed, Embase, Cochrane, Web of Science and SinoMed (Chinese Biomedical Database) from inception until 28 November 2016. The literature searches were conducted by a combination of medical subject headings (MeSH) and free terms such as “malignancy”, “neoplasm”, “cancer”, “antiviral”, “hepatitis B virus” and “reactivation”. We had not restricted languages in the course of searching. All the references identified were managed by Endnote. More details are available in S1 Appendix Data.

Outcomes and definitions
The primary outcomes were the rates of HBVR and the risk ratio (RR) of HBVR comparing the antiviral prophylaxis group with the non-prophylaxis group, and the secondary outcomes were the RR of hepatitis, chemotherapy disruption and mortality. HBVR was considered as an increase in the HBV DNA level of ten-times or more when compared with the baseline level or an absolute increase in the HBV DNA level that exceeded \(1 \times 10^9\) copies/mL without other systemic infections. Hepatitis was characterized by three times or more increase in serum ALT levels that exceeded the upper limit of normal (ULN) or an absolute rise of ALT to more than 100 U/L. Disruption of chemotherapy was defined as delay 8 or more days in planned chemotherapy regimens and premature termination of chemotherapy. Mortality was defined as death due to HBVR, excluded other causes related mortality, including cancer-related and other systemic infections related mortality. Besides, antiviral prophylaxis was defined as received antiviral medicine daily prior to the commencement of chemotherapy, and continued throughout the course of chemotherapy or last longer.

Inclusion and exclusion criteria
Eligible studies include randomized and non-randomized clinical studies that had investigated the HBVR with or without antiviral prophylaxis in HBsAg-positive lung cancer patients during chemotherapy. Studies must have reported data on HBVR for lung cancer. Studies were excluded: (1) Case reports, reviews and conference reports. (2) No control group or unable to extract relevant data. (3) Cases coexist of HAV, HCV, HDV or HIV infection.

Study selection
All 3701 references were identified after searched databases. After duplicates removed, we reviewed of titles and abstracts, and scanned the full text according to the inclusion/exclusion criteria. Finally, total 11 studies[7–10, 17–23] included in the meta-analysis (Fig 1).

Data collection and quality assessment
Two investigators (X.L and Z.L) independently assessed the eligible studies and extracted data using electronic tables. The following items were summarized: age, gender, type of study design, type of cancer, sample size, basic characteristics HBV DNA level, hepatic function, intervention regimen and outcome.

Two investigators (Z.X and W.D) independently assessed the quality of the included studies using the Newcastle-Ottawa scale (NOS). The NOS has three parameters of quality assessment for prospective or retrospective cohort studies, and assigns a maximum of four points for selection, two points for comparability and three points for outcome. NOS scores of \(\geq 7\) points were considered to be high quality studies and 5–6 points were moderate quality. A third investigator (Y.W) was consulted when disagreement arise.
Statistical analysis

All outcomes were dichotomous variables and presented as absolute risk and RR with 95% confidence intervals (CI). The associated data statistics and potential publication bias evaluation were conducted by the Cochrane Collaboration’s Review Manager Software (RevMan, version 5.3; Oxford, United Kingdom) and the metafor and meta packages in R software (version 3.3.2, R Foundation for Statistical Computing). Probability values were two-sided, and P<0.05 was considered of statistical significance. Statistical heterogeneity was evaluated using the I-squared ($I^2$) and chi-squared ($\chi^2$) tests. $I^2$ values of 25%, 50%, 75% indicated low, moderate and high level of heterogeneity, respectively. Data were not pooled if $I^2$ was greater than 40%. A P value of <0.1 for $\chi^2$ was defined to indicate the presence of heterogeneity. Results were pooled using the maximum likelihood estimation, a fixed effect model was used if no heterogeneity existed[26]. Besides, sensitivity analysis was performed if significant heterogeneity existed. Funnel plots and the Egger’s test of funnel plot asymmetry were used to evaluated publication bias[27].
Results

Studies characteristics

In total, 11 studies met the strict inclusion criteria and comprised 794 HBsAg-positive lung cancer patients in the meta-analysis (Fig 1), of which 5 studies were published in Chinese with an English abstract.

We summarized baseline study characteristics (Table 1) and extracted data (S1 Table). Of the 11 studies, 9 were retrospective cohorts and 2 were prospective cohorts. Seven studies were two arms and 4 studies were single arm with non-prophylaxis group. The 11 studies included 6 from mainland China, 2 from Hongkong, 3 from Greece, Turkey and Japan, respectively. All of the 794 patients were HBsAg-seropositive, the median age was 51 years (range 17 to 79 years), with 468 male, 280 female and 46 undescribed. Of the 794 patients, 326 patients received antiviral prophylaxis, of which 211 received lamivudine and 115 received entecavir, besides, 468 patients did not received antiviral prophylaxis.

We used NOS to assess the quality of included studies (S2 Table). According to NOS assessments, all of the studies were of moderate or high quality, which indicated that all the included studies were reliable. As for publication bias assessment, symmetrical funnel plot analysis of different outcomes (S1–S3 Figs) and Egger’s tests (P > 0.05) showed no significant publication bias was found. No significant between-study heterogeneity was found (I^2 = 0%), and the fixed-effect model was applied.

Absolute risk for HBVR

In all, 11 studies, included 468 patients, reported HBVR without antiviral prophylaxis. The risk for HBVR ranged from 0% to 38% in 11 studies. The pooled risk for HBVR was 21% (95% CI: 0.17–0.25) (Fig 2A).

All of 7 studies, included 326 patients, reported HBVR with antiviral prophylaxis. The risk was much lower when conducted antiviral prophylaxis, ranged from 0% to 7%, the pooled risk for HBVR was 4% (95% CI: 0.02–0.06) (Fig 2B). The results revealed that patients with antiviral prophylaxis had a much lower risk of HBVR, the pooled risk for HBVR with and without antiviral prophylaxis were 4% and 21%, respectively.

Absolute risk for HBVR, by area subgroup

When considering the included studies were mostly from mainland China, and China has a high prevalence rate of HBV[3], we examined HBVR without antiviral prophylaxis by area subgroup. In the mainland China group, 6 studies, including 427 patients, reported the risk for HBVR ranged from 19% to 27%, the pooled risk for HBVR was 21% (95% CI: 0.17–0.25) (S4 Fig). In the other regions group, 5 studies, including 2 from Hongkong, 3 from Greece, Turkey and Japan respectively, reported the risk for HBVR ranged from 0% to 38%, the pooled risk for HBVR was 19% (95% CI: 0.07–0.31) (S4 Fig). Beside, we pooled the risk for HBVR in Asians by excluding two studies not from Asia[7, 17], the pooled risk was same with the risk pooled in the mainland China group 21% (95% CI: 0.17–0.25) (S5 Fig).

Risk ratio of HBVR comparing antiviral prophylaxis with non-prophylaxis

In total, 7 studies had compared HBVR risk in patients receiving antiviral prophylaxis versus non-prophylaxis, including 326 patients in the antiviral prophylaxis group and 431 patients in the non-prophylaxis group. The meta-analysis showed that patients with antiviral prophylaxis had a substantial reduction in the risk of HBVR, the pooled RR was 0.22 (95% CI: 0.13–0.37,
| Study, Year (Reference) | Country | Study Design | Type of cancer | Testing result of HBsAg† | Total Group (P/C)† | Age(y) | Sex (M/F)† | Pre-chemo† | Post-chemo Intervention | Median follow-up (m)† | HBV† DNA (Units) | ALT† (IU/L) | TBIL† (Units) | HBV DNA (Units) | ALT (IU/L) | TBIL (Units) | Dosage Duration |
|------------------------|---------|--------------|----------------|-------------------------|-------------------|-------|------------|-----------|-------------------------|-------------------|----------------|-------------|-------------|----------------|-------------|-------------|----------------|
| Alexopoulos et al, 1999 | Greece  | Retrospective Cohort, Single | LC, HBSAg+ | HBsAg+ | NR/14 | NR/14 | 30/50 | T: 58 (19–78) | 12m | 1.5m after chemo. | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before chemo. End: 6m after chemo. |
| Che et al, 2014 | China | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 160 | 80/80 | P: 39/43 | T: 36/24 | NR | Entecavir 0.5mg/d | NR | NR | NR | NR | NR | NR | Entecavir |
| Duan et al, 2009 | China | Prospective Cohort, Double | IIIA NSCLC, HBSAg+ | HBsAg+ | 60 | 30/30 | T: 56 (35–71) | NR | P: 34.8 ± 23.5 | 12m | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before confirmed diagnosis. End: 6m after chemo. |
| Eren et al, 2009 | Turkey | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 11 | 7/4 | NR | NR | NR | LAM 100mg/d | NR | NR | NR | NR | NR | NR | Start: before chemo. End: 6m after chemo. |
| Fan et al, 2009 | China | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 258 | 82/176 | P: 49/30 | T: 51/29 | NR | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before chemo. End: 3m after chemo. |
| Lin et al, 2014 | China | Retrospective Cohort, Double | IIIB IV NSCLC, HBSAg+ | HBsAg+ | 2 | NR2 | P: NR | 36/29 | P: 51pt | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: within 7d before chemo. End: 2m after chemo. |
| Nishida et al, 2013 | Japan | Retrospective Cohort, Single | LC, HBSAg+ | HBsAg+ | 2 | NR2 | C: 51 | P: NR | C: 116pt | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before chemo. End: NR. |
| Yan et al, 2012 | China | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 76 | 33/43 | P: 29/34 | T: 47pt | <60y | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before chemo. End: NR. |
| Yeo et al, 2000 | China (Hongkong) | Retrospective Cohort, Single | LC, HBSAg+ | HBsAg+ | 8 | NR8 | C: 51 | P: NR | C: 60pt | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: within 7d before chemo. End: 2m after chemo. |
| Yeo et al, 2004 | China (Hongkong) | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 13 | NR13 | 35/10 | P: NR | C: 51 | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: within 7d before chemo. End: 2m after chemo. |
| Zheng et al, 2014 | China | Retrospective Cohort, Double | LC, HBSAg+ | HBsAg+ | 122 | 59/63 | P: 49/41 | T: 75pt | <60y | NR | NR | NR | NR | NR | NR | LAM 100mg/d | Start: before chemo. End: 22m (median 10m). |
Table 1. (Continued)

| Study, Year (Reference) | Country | Study Design | Type of cancer Testing result of HBsAg† | Total (n) | Group (P/C) † | Sex (M/F) † | Age(y) † | Pre-chemo† | Post-chemo | Intervention | Dosage | Duration | Median follow-up (m) † |
|-------------------------|---------|--------------|-----------------------------------------|----------|--------------|-------------|-----------|------------|------------|-------------|--------|----------|------------------------|
| Zheng et al, 2016       | China   | RetrospectiveCohort, Double | LC HBsAg+ | 70 | 35/35 | T: 39/31 | T: 55.6(26–79) | NR | P: 37.4 ±4.4C: 37.1±7.8 | P:17.8 ±3.2C: 17.6 ±3.3 | NR | P: 71.6 ±4.9C: 104.6 ±10.9 | P:73.8 ±7.4C:98.8 ±11.6 | Entecavir 0.5mg/d | Start: 7d before chemo. End: 1m after chemo. |

†Measurement data were presented as mean± SD or median(range).

Single = single group study; Double = double group study; P = prophylaxis group; C = control group; T = total, prophylaxis group and control group; pt = patient(s); M = male; F = female; d = day(s); m = month(s); y = year(s); HBV = hepatic B virus; ALT = alanine aminotransferase; TBIL = total bilirubin level; LC = lung cancer; NSCLC = non-small cell lung cancer; HBsAg = hepatic B virus surface antibody; LAM = lamivudine; chmo = chemotherapy; NR = not reported;

https://doi.org/10.1371/journal.pone.0179680.t001
Fig 2. Absolute risk for HBV reactivation in HBsAg-positive lung cancer patients without (2A) or with (2B) antiviral prophylaxis.

https://doi.org/10.1371/journal.pone.0179680.g002
Risk ratio of hepatitis comparing antiviral prophylaxis with non-prophylaxis

Three studies, including 540 patients, reported the incidence of hepatitis. There was a 5% to 45% risk for hepatitis without antiviral prophylaxis, while 0% to 18% risk with antiviral prophylaxis. The incidence of hepatitis in patients with antiviral prophylaxis was significantly lower than without prophylaxis, the pooled RR was 0.35 (95% CI: 0.22–0.56, \(p<0.0001\)) (Fig 3). Further, no single study was found to significantly alter the overall pooled effect.

Risk ratio of chemotherapy disruption comparing antiviral prophylaxis with non-prophylaxis

Four studies reported on disruptions of chemotherapy. The risk for chemotherapy disruptions ranged from 2% to 33% without antiviral prophylaxis, while the risk ranged from 0% to 9% with antiviral prophylaxis. Meta-analysis revealed that patients with antiviral prophylaxis had a substantial reduction in the risk of chemotherapy disruption, the pooled RR was 0.29 (95% CI: 0.15–0.55, \(p<0.0002\)) (Fig 4).

The mortality

Not enough studies were available to pool for the relevant mortality. Mortality information was reported by three studies\([10, 18, 22]\). According to Lin et al\([10]\), 4 patients died from HBV-related fulminant hepatitis in non-prophylaxis group, but no significant difference in mortality due to reactivation was noted between patients with or without prophylaxis. Zheng et al\([22]\) reported 92 deaths until the end of 22 months follow-up, but they did not state whether the deaths were HBV-related. Che et al\([18]\) reported no HBV-related death during chemotherapy.

Discussion

The chemotherapy-induced HBV reactivation may hinder the continuation of the anticancer program. Once HBV reactivation occurred during chemotherapy, it would cause hepatitis or
even death which would undoubtedly lead to a negative prognosis of cancer\cite{28}. Several meta-analysis\cite{5, 12–14} noted the risk of HBVR and the effectiveness of antiviral prophylaxis in patients with hematological and solid malignancies, especially in patients with lymphoma and breast cancer. However, we knew little about HBVR and antiviral prophylaxis in lung cancer. Our meta-analysis shows that the risks of HBVR in the control group and antiviral prophylaxis group were 21\% and 4\%, respectively. Thus, the risk for HBVR in HBsAg-positive lung cancer patients receiving chemotherapy is very high, and approximately 81\% of reactivations can be prevented with antiviral prophylaxis in initiation of chemotherapy. Furthermore, it is also proved that antiviral prophylaxis had substantially lowered the risk for HBVR (RR, 0.22 [95\% CI, 0.13–0.37], p< 0.0001), hepatitis (RR, 0.35 [95\% CI, 0.22–0.56], p< 0.0001) and chemotherapy disruption (RR, 0.29 [95\% CI, 0.15–0.55], p< 0.0002) compared to those without antiviral prophylaxis. We were not able to pool the mortality due to the incomplete variables from the included studies. Therefore, all available evidences in this study showed that the risk for HBVR and relevant complications are high in HBsAg-positive lung cancer patients receiving chemotherapy, and HBV screening for antiviral prophylaxis should be carried out before initiation of chemotherapy for lung cancer patients.

Appropriate prechemotherapy screening strategy for HBV may be an effective measure to distinguish high-risk populations, especially in areas highly endemic with HBV, such as Asia-Pacific and Africa regions\cite{2, 3, 6}. Although, nucleos(t)ide analogues are effective therapeutic measures for HBVR, the development of HBVR invariably means that anticancer treatment is disrupted, with delay at the least and premature termination in the more severe circumstances \cite{29}. Therefore, antiviral preventing the occurrence of HBVR may provide a more practical approach in managing HBsAg-seropositive patients who require chemotherapy\cite{29}. Previous studies had reported the comparison with and without antiviral prophylaxis in hematological and certain solid malignancies\cite{12, 14, 30}. Our meta-analysis firstly reported the increased

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|c|c|}
\hline
Study or Subgroup & Antiviral Prophylaxis & & & & & & & \\
& Events & Total & Weight & Risk Ratio & & & \\
& & & & & & & & \\
\hline
\hline
1.2.1 Hepatitis & & & & & & & & \\
Che et al, 2014 & 14 & 80 & 36 & 80 & 36.9\% & 0.39 [0.23, 0.66] & & \\
Lin et al, 2014 & 5 & 82 & 34 & 176 & 22.2\% & 0.32 [0.13, 0.78] & & \\
Zheng et al, 2014 & 0 & 59 & 3 & 63 & 3.5\% & 0.15 [0.01, 2.89] & & \\
Subtotal (95\% CI) & 221 & 319 & 62.6\% & & 0.35 [0.22, 0.56] & & \\
Total events & 19 & 73 & & & & & & \\
Heterogeneity: Chi$^2$ = 0.51, df = 2 (P = 0.78); I$^2$ = 0\% \\
Test for overall effect: Z = 4.45 (P < 0.00001) & & & & & & & & \\
\hline
1.2.2 Chemotherapy disruption & & & & & & & & \\
Che et al, 2014 & 4 & 80 & 16 & 80 & 16.4\% & 0.25 [0.09, 0.72] & & \\
Duan et al, 2009 & 3 & 30 & 10 & 30 & 10.3\% & 0.30 [0.09, 0.98] & & \\
Zheng et al, 2014 & 0 & 59 & 1 & 63 & 1.5\% & 0.36 [0.01, 8.56] & & \\
Zheng et al, 2016 & 3 & 35 & 9 & 35 & 9.2\% & 0.33 [0.10, 1.13] & & \\
Subtotal (95\% CI) & 204 & 208 & 37.4\% & & 0.29 [0.15, 0.55] & & \\
Total events & 10 & 36 & & & & & & \\
Heterogeneity: Chi$^2$ = 0.15, df = 3 (P = 0.99); I$^2$ = 0\% \\
Test for overall effect: Z = 3.76 (P = 0.0002) & & & & & & & & \\
\hline
Total (95\% CI) & 425 & 527 & 100.0\% & & 0.33 [0.22, 0.48] & & \\
Total events & 29 & 109 & & & & & & \\
Heterogeneity: Chi$^2$ = 0.94, df = 6 (P = 0.99); I$^2$ = 0\% \\
Test for overall effect: Z = 5.83 (P < 0.0001) \\
Test for subarous differences: Chi$^2$ = 2.3, df = 1 (P = 0.64); I$^2$ = 0\% \\
\hline
\end{tabular}
\caption{Risk ratio of hepatitis and chemotherapy disruption comparing antiviral prophylaxis with non-prophylaxis in HBsAg-positive lung cancer patients.}
\end{table}

https://doi.org/10.1371/journal.pone.0179680.g004
risk for HBVR and the benefit of antiviral prophylaxis in HBsAg-seropositive lung cancer patients receiving chemotherapy.

In consideration of most included studies were from Asia, we pooled the incidence of HBVR in the control group after excluding two studies not from Asia[7, 17], and yielded similar results. Due to limited data in the included studies, we were not able to analyze the incidence of HBVR by different chemotherapy regimens. As previously reported, anthracyclines or corticosteroids were more vulnerable to induce HBVR[29–31], both anthracyclines and corticosteroids are commonly used as part of the anticancer treatment and antiemetic premedication for patients who have hematological and solid malignancies[29]. As Paul et al[13] reported, anthracycline-based chemotherapy had a median reactivation risk of 29%, and the platinum-based regimen, which used commonly in lung cancer chemotherapy, had a median reactivation risk of 25%. Additionally, other risk factors for HBVR in patients undergoing chemotherapy have been postulated, including ALT level, baseline HBV DNA level, HBsAg-seropositivity, HBV e antigen seropositivity, precore mutant strain, viral genotype, male sex and young age[28, 32].

Currently, there are no extensive applied screening and prophylaxis recommendation. Several specialty societies[6, 11, 33–36] had recommended HBV screening in HBV-infection high risk patients or if the immunosuppression caused by the treatment is expected to be high. Apart from this general recommendation, the guidelines, given the inaccuracies in ascertaining risks for HBV infection, do not demonstrate unanimous consent in offering HBV screening for all patients undergoing chemotherapy[28]. However, if patients receiving chemotherapy are considered at high risk for HBVR, the screening strategy should be universal[28, 32]. Further, the optimal screening items, initiation and duration of antiviral treatment were controversial. Details of the guidelines are presented in Table 2.

The cost-effectiveness is an important issue when considering universal HBV screening before chemotherapy. According to cost-effectiveness investigation in Australia[37], universal prechemotherapy HBV screening was not cost-effective for patients with solid tumors. However, considering lower than 2% incidence of HBV infection in Australia and higher than 8% prevalence of HBV in Asia, Africa and Pacific Islands[36, 38], the conclusion could not be generalized imprudently. Another cost-effectiveness analysis noted that universal screening and prophylactic to prevent reactivation was the most cost-effective strategy, which would prevent a significant number of reactivations and may extend the lives of cancer patients[39]. However, an appropriate screening strategy remains controversial[32]. Our results support universal screening for lung cancer patients before chemotherapy, although the cost-effectiveness should be evaluated in future studies. However, regarding the moment for testing, it has been suggested that the major benefit is acquired when it is done prior to initiation of chemotherapy[32].

To our knowledge, there has not been meta-analysis systematically investigating the increased risk for HBVR and the prophylactic effects of antiviral drugs in HBsAg-positive lung cancer patients undergoing chemotherapy. We first demonstrated the incidence of HBVR and the prophylactic effect of antiviral treatment in reducing the risk of reactivation and relevant clinical complications in HBsAg-positive lung cancer patients during chemotherapy. The current meta-analysis supports appropriate HBV screening before chemotherapy for lung cancer patients, and antiviral prophylaxis for those with confirmed HBsAg-seropositive.

Our meta-analysis has several limitations. First, included studies were all cohort studies, large prospective randomized trials were lacking. Second, most of study populations were from mainland China, further study should be conducted to investigate other population out of Asia. Third, we were not able to analyze interesting outcomes according to stratification for gender, age, tumor stage and chemotherapy regimens due to unavailable data. Finally, we were
### Table 2. Hepatitis B virus screening and antiviral prophylaxis strategy prior to immunosuppressive therapy by different major guidelines.

| Guidelines                          | Screening Strategy                                                                 | Prophylaxis Strategy                                                                 | Antiviral duration |
|-------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|--------------------|
| AASLD (Lok et al, 2009) [33]        | HBV high risk patients before chemotherapy or immunosuppressive therapy.           | HBV carriers.                                                                         | Start: Before the initiation of cancer chemotherapy or immunosuppressive therapy, **End:** For six months after the completion of chemotherapy or immunosuppressive therapy if baseline HBV DNA < 2000UI/mL. Patients with HBV DNA baseline value > 2000UI/mL should continue treatment as immunocompetent patients. |
|                                     | HBsAg; anti-HBc.                                                                   | **Start:** Before the initiation of cancer chemotherapy or immunosuppressive therapy. **End:** Antiviral therapy should continue for as long as required for management for underlying chronic disease in HBsAg positive patients. In other patients, prophylaxis should continue for at least six months after stopping chemotherapy. |
| AASLD (Hoofnagle, 2009) [34]        | All patients undergoing cancer chemotherapy and marked immunosuppressive treatments. | HBsAg positive patients should be evaluated for indications for HBV treatment and started on appropriate therapy. Inactive HBsAg carriers should receive antiviral prophylaxis. HBsAg negative and anti-HBc positive patients with undetectable HBV DNA should be considered for antiviral treatments if aggressive or long term chemotherapy/immunosuppression are expected. | **Start:** Before the initiation of cancer chemotherapy or immunosuppressive therapy. **End:** Antiviral therapy should continue for as long as required for management for underlying chronic disease in HBsAg positive patients. In other patients, prophylaxis should continue for at least six months after stopping chemotherapy. |
|                                     | HBsAg; anti-HBc.                                                                   | In HBV chronic patients, an antiviral treatment should be considered to reduce the risk of HBV reactivation, although evidence is limited. | Screening and/or treating should not delay the initiation of chemotherapy. |
| ASCO (Artz et al, 2010) [11]        | Insufficient evidence to determine the benefits and the harms of routine screening in patients undergoing chemotherapy or immunosuppressive treatments. HBV screening requires clinical judgment. May be considered in HBV high risk patients or if highly immunosuppressive therapy is planned. | HBsAg. In some populations, testing for anti-HBc should also be considered. Testing for anti-HBs in anti-HBc positive patients. | **Start:** Preemptive before the start of chemotherapy and immunosuppressive regardless of HBV DNA levels. **End:** 12 months after cessation of chemotherapy and immunosuppressive. |
| EASL (European Association for the Study of the Liver, 2012) [35] | All candidates for chemotherapy and immunosuppressive treatments.                  | HBsAg, anti-HBc. HBsAg positive candidates for chemotherapy and immunosuppressive therapy should be tested for HBV DNA levels. | **Start:** Preemptive before the start of chemotherapy and immunosuppressive regardless of HBV DNA levels. **End:** 12 months after cessation of chemotherapy and immunosuppressive. |
|                                     | HBsAg; anti-HBc. HBsAg positive patients should receive preemptive antiviral treatment regardless of HBV DNA level. HBsAg negative and anti-HBc positive patients with detectable should be treated as HBsAg positive patients. HBsAg negative and anti-HBc positive patients with undetectable HBV DNA should be closely monitored. | In HBV chronic patients, an antiviral treatment should be considered to reduce the risk of HBV reactivation, although evidence is limited. | Screening and/or treating should not delay the initiation of chemotherapy. |
| APASL (Sarin et al, 2016) [3]       | Persons needing immunosuppressive or cancer chemotherapy.                          | Testing should include a serological assay for HBsAg and anti-HBc prior to initiation of treatment. HBsAg-negative patients with positive anti-HBc should be tested for HBV DNA. | **Start:** Before the start of immunosuppression or chemotherapy. **End:** During therapy and for 12 months after cessation of cancer therapy. |
|                                     | HBsAg-positive patients who receive cytotoxic or immunosuppressive therapy. HBsAg-negative, anti-HBc positive patients with detectable HBV DNA should be treated as HBsAg-positive patients. HBsAg-negative, anti-HBc positive patients with undetectable HBV DNA should be followed carefully. | HBsAg-positive patients who receive antiviral prophylaxis. Patients anti-HBc positive should be closely monitored. | **Start:** Before the start of immunosuppression or chemotherapy. **End:** During therapy and for 12 months after cessation of cancer therapy. |
| CDC (Weinbaum et al, 2009) [36]     | All patients needing immunosuppressive treatments should undergo serologic testing. | HBsAg; anti-HBc; anti-HBs. All patients HBsAg positive should receive antiviral prophylaxis. Patients anti-HBc positive should be closely monitored. | **Start:** - |

**AASLD:** American Association for the Study of Liver Disease; **ASCO:** American Society Clinical Oncology; **EASL:** European Association for the Study of the Liver; **APASL:** Asian Pacific Association for the Study of the Liver; **CDC:** Center for Disease Control; **HBV:** Hepatitis B virus; **HBsAg:** Hepatitis B surface antigen; **anti-HBc:** Antibody to hepatitis B core antigen; **anti-HBs:** Antibody to hepatitis B surface antigen.

https://doi.org/10.1371/journal.pone.0179680.1002
not able to assess the optimal initiation and duration of antiviral therapy for those patients due to a lack of relevant data in the included studies. Further investigations should supplement relevant knowledge about these fields.

Conclusions
In summary, our study demonstrated the increased risk for HBVR and effectiveness of antiviral prophylaxis in HBsAg-positive lung cancer patients undergoing chemotherapy. Our meta-analysis results indicated that the risk for HBVR was substantially higher comparing no antiviral prophylaxis with antiviral prophylaxis, and antiviral prophylaxis significantly reduced the risk for HBVR, hepatitis and chemotherapy disruption. Therefore, we believe that our results support antiviral prophylaxis for parallel patient populations. Besides, we suggest appropriate HBV screening strategy in lung cancer populations before initiation of chemotherapy.

Supporting information
S1 Fig. The funnel plot of eleven studies included in absolute risk analysis in no antiviral prophylaxis group.
(TIFF)
S2 Fig. The funnel plot of seven studies included in absolute risk analysis in antiviral prophylaxis group.
(TIFF)
S3 Fig. The funnel plot of seven studies included in risk ratio analysis for HBV reactivation.
(TIFF)
S4 Fig. Absolute risk for HBV reactivation in HBsAg-positive lung cancer patients without antiviral prophylaxis, by area subgroup.
(TIFF)
S5 Fig. Absolute risk for HBV reactivation in HBsAg-positive lung cancer patients without antiviral prophylaxis in Asians.
(TIFF)
S1 Table. The results for primary and secondary outcomes of the clinical studies.
(XLSX)
S2 Table. Quality assessment of the included studies using the Newcastle-Ottawa scale in cohort studies.
(XLSX)
S1 Appendix Data. search strategies.
(DOCX)
S1 File. PRISMA 2009 checklist.
(DOC)

Author Contributions
Conceptualization: Ling-quan Kong.
Data curation: Yu-tuan Wu, Xin Li, Zi-li Liu, Zhou Xu, Wei Dai, Ling-quan Kong.
Formal analysis: Yu-tuan Wu, Xin Li, Zi-li Liu, Zhou Xu, Wei Dai, Ling-quan Kong.

Funding acquisition: Yu-tuan Wu, Ling-quan Kong.

Investigation: Yu-tuan Wu, Xin Li, Zi-li Liu.

Methodology: Yu-tuan Wu, Zhou Xu, Wei Dai.

Project administration: Kai-nan Wu, Ling-quan Kong.

Resources: Kai-nan Wu, Ling-quan Kong.

Software: Yu-tuan Wu, Xin Li, Zi-li Liu.

Supervision: Ling-quan Kong.

Validation: Yu-tuan Wu, Xin Li, Zi-li Liu, Zhou Xu, Wei Dai, Ling-quan Kong.

Visualization: Yu-tuan Wu, Zhou Xu, Wei Dai.

Writing – review & editing: Yu-tuan Wu, Ke Zhang, Jiup-song Wu, Bilal Arshad, Ling-quan Kong.

References

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. The Lancet. 2015; 386(10003):1546–55. https://doi.org/10.1016/s0140-6736(15)61412-x

2. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing countries. World Journal of Gastroenterology. 2015; 21(42):11941–53. https://doi.org/10.3748/wjg.v21.i42.11941 PMID: 26576083

3. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. Journal of Gastroenterology and Hepatology. 2013; 28 Suppl 1(Supplement):7–10.

4. Mozessohn L, Chan KK, Feld JJ, Hicks JK. Hepatitis B reactivation in patients with lymphoma: A meta-analysis. Journal of Clinical Oncology. 2013; 31(31).

5. Chen WC, Cheng JS, Chiang PH, Tsay FW, Chan HH, Chang HW, et al. A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy. PLoS ONE. 2015; 10(6).

6. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016; 10(1):1–98. https://doi.org/10.1007/s12072-015-9675-4 PMID: 26563120.

7. Eren OO, Artac M, Boruban MC, Yavas O, Arslan U, Basaranoglu M. Chemotherapy-induced Hepatitis B virus reactivation in HbsAg positive cancer patients: A single center experience. Medical Oncology. 2009; 26(4):386–92. https://doi.org/10.1007/s12032-008-9133-4 PMID: 19021003

8. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000; 62(3):299–307. Epub 2000/10/31. PMID: 11055239.

9. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associated with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004; 90(7):1306–11. Epub 2004/04/01. https://doi.org/10.1038/sj.bjc.6601699 PMID: 15054446.

10. Lin GN, Peng JW, Xiao JJ, Liu DY, Xie ZJ. Hepatitis B virus reactivation in hepatitis B surface antigen seropositive patients with metastatic non-small cell lung cancer receiving cytotoxic chemotherapy: the efficacy of preemptive lamivudine and identification of risk factors. Medical oncology (Northwood, London, England) [Internet]. 2014; 31(8):[119 p.].

11. Arzt AS, Somerfield MR, Feld JJ, Giusti AF, Kramer BS, Sabichi AL, et al. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010; 28(19):3199–202. Epub 2010/06/03. https://doi.org/10.1200/JCO.2010.30.0673 PMID: 20516452.

12. Li H, Zhang HM, Chen LF, Chen YQ, Chen L, Ren H, et al. Prophylactic lamivudine to improve the outcome of HBsAg-positive lymphoma patients during chemotherapy: A systematic review and meta-
13. Paul S, Saxena A, Terrin N, Viveiros K, Baik EM, Wong JB. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: A systematic review and meta-analysis. Annals of Internal Medicine. 2016; 164(1):30–40. https://doi.org/10.7326/M15-1121 PMID: 26595058

14. Zheng Y, Zhang S, Grahn HMT, Ye C, Gong Z, Zhang Q. Prophylactic lamivudine to improve the outcome of breast cancer patients with HBsAg positive during chemotherapy: A meta-analysis. Hepatitis Monthly. 2013; 13(3).

15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016; 66(1):7–30. Epub 2016/01/09. https://doi.org/10.3322/caac.21332 PMID: 26742998.

16. Schwartz AG, Cote ML. Epidemiology of Lung Cancer. Adv Exp Med Biol. 2016; 893:21–41. https://doi.org/10.1007/978-3-319-24223-1_2 PMID: 26667337.

17. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. British Journal of Cancer. 1999; 81(1):69–74. https://doi.org/10.1038/sj.bjc.6690652 PMID: 10487614.

18. Dehai Che, Zhen Li, Gang Xu, Yan Yu, Hua Zhang, Yan L. A clinical study of preventive effect of entecavir on HBV reactivation in lung cancer with HBV carriers after chemotherapy. Practical Oncology Journal. 2014; 28(1):7–11.

19. Duan L, Li G, Zhang Y, Ye L. The clinical applications of combined HBV approach to chemotherapy for non-small cell lung cancer while adoption of antivirus therapy. Chinese Journal of Lung Cancer. 2009; 12(8):893–5.

20. Nishida T, Hiramatsu N, Mizuki M, Nagatomo I, Kida H, Tazumi K, et al. Managing hepatitis B virus carriers with systemic chemotherapy or biologic therapy in the outpatient clinic. Hepatology Research. 2013; 43(4):339–46.

21. Yan Y, Zhang J, Zhao H, Huang Y, Hu Z, Zhang L. Retrospective analysis of the correlation between hepatitis B Virus infection and chemotherapy-induced hepatic injury in patients with lung cancer. Chinese Journal of Clinical Oncology. 2012; 39(8):465–8.

22. Zheng L, Zhang BB, Song ZB, He CX, Lou GY, Yu XM, et al. Clinical analysis of application of antiviral drugs in lung cancer patients with hepatitis B virus infection who receiving chemotherapy. Chinese Journal of Cancer Prevention and Treatment. 2014; 21(10):771–4.

23. Liang Zheng, Haijun L. Effect of entecavir on lung cancer in hepatitis B virus carriers during chemotherapy. Medical Journal of Qilu. 2016; (1):4–5,9.

24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association. 2000; 283(15):2008–12. PMID: 10789670.

25. Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Systematic reviews. 2012; 1:2. Epub 2012/05/17. https://doi.org/10.1186/2046-4053-1-2 PMID: 22587842.

26. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7(3):177–88. PMID: 3802833.

27. Egger M. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629–34. PMID: 9310563.

28. Bozza C, Cinaussero M, Iacono D, Puglisi F. Hepatitis B and cancer: A practical guide for the oncologist. Critical Reviews in Oncology/hematology. 2016; 98:137–46. https://doi.org/10.1016/j.critrevonc.2015.10.017 PMID: 26657667.

29. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006; 43(2):209–20. https://doi.org/10.1002/hep.21051 PMID: 16440366.

30. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. British Journal of Haematology. 2001; 115(1):58–62. PMID: 11722410.

31. Ling WH, Soe PP, Pang AS, Lee SC. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013; 108(10):1931–5. https://doi.org/10.1038/bjc.2013.225 PMID: 23652302.

32. Bessone F, Dirchwolf M. Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations. World journal of hepatology. 2016; 8(8):385–94. Epub 2016/03/24. https://doi.org/10.4254/wjh.v8.i8.385 PMID: 27004086.
33. Lok ASF, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology. 2009; 50(3):661–2. https://doi.org/10.1002/hep.23190 PMID: 19714720

34. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009; 49(S5):S156–S65. https://doi.org/10.1002/hep.22945 PMID: 19399803

35. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology. 2012; 57(1):167–85. https://doi.org/10.1016/j.jhep.2012.02.010 PMID: 22436845

36. Weinbaum C MW I, Mast E E, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection[J]. MMWR Recomm Rep. 2008; 57(RR-8):1–20. PMID: 18802412

37. Day FL, Karnon J, Rischin D. Cost-effectiveness of universal hepatitis B virus screening in patients beginning chemotherapy for solid tumors. Journal of Clinical Oncology. 2011; 29(24):3270–7. https://doi.org/10.1200/JCO.2011.35.1635 PMID: 21788556

38. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Reviews. 2006; 28(1):112–25.

39. Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, et al. Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Res Treat. 2015; 151(3):639–52. Epub 2015/05/13. https://doi.org/10.1007/s10549-015-3382-7 PMID: 25962692.